QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: GVP Module XVI — Routine and Additional Risk Minimisation Measures

Test your understanding of the concepts covered by GVP Module XVI: Routine and Additional Risk Minimisation Measures.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A medication error occurs because a complex preparation process leads to incorrect concentration before administration. Which design principle is most relevant when selecting an additional RMM?

Direct the intervention primarily to the general public because all safety information should be publicly available Choose the most restrictive available control regardless of where the error occurs Target the person and step in the preparation or administration pathway where the error can be prevented Rely exclusively on a general description of the adverse reaction in the package leaflet

Question 2 of 10 At which point should the organisation define what evidence would lead it to maintain, modify, intensify or remove an additional RMM?

Only after the programme has ended When the measure is designed, as part of prospective evaluation and governance Only if an inspector requests the information After the first distribution record has been completed

Question 3 of 10 When might one safety concern appropriately require multiple risk minimisation measures?

When the organisation wants to demonstrate a high volume of activity regardless of the causal pathway When different interventions are needed to influence separate points in the pathway leading to the adverse outcome Only when each measure is directed to exactly the same audience and action Only when routine product information has been removed

Question 4 of 10 Why is early engagement of patients and healthcare professionals valuable when developing an additional RMM?

They can identify practical barriers and workflow constraints that may not be apparent from a regulatory perspective Their involvement eliminates the need for a documented scientific rationale They determine whether an intervention is legally authorised throughout the EU Their participation guarantees that the measure will change health outcomes

Question 5 of 10 What is the most appropriate starting point when designing risk minimisation for a medicinal product?

Selecting an educational leaflet template Identifying the preferred regulatory communication channel Characterising the safety concern, including its preventability, affected population and circumstances of exposure Determining how many materials can be distributed within the available budget

Question 6 of 10 A company reports that an educational programme reached 95% of its intended healthcare professionals and concludes that it was effective. What is the key limitation of this conclusion?

Distribution data cannot demonstrate that recipients understood the message or changed behaviour High distribution automatically invalidates the programme Effectiveness can only be assessed through spontaneous adverse-event reporting Healthcare-professional recipients are not relevant to risk minimisation

Question 7 of 10 Which situation most clearly indicates that an additional RMM should be reconsidered within the benefit-risk lifecycle?

The measure has remained unchanged for years, although new evidence suggests the risk and its effectiveness may have changed The measure has an approved design and therefore cannot be modified The measure is documented in the RMP, so further assessment is unnecessary The measure has been distributed once and no further evidence is available

Question 8 of 10 What distinguishes an educational or safety-advice tool from routine product information?

It provides targeted information or instructions beyond routine product information because additional communication is necessary to manage the risk It contains promotional information intended to increase appropriate product use It is automatically required whenever the adverse reaction is serious It is intended to replace the SmPC and package leaflet

Question 9 of 10 Which statement best describes the relationship between an RMM and the risk management plan?

Listing an RMM in the RMP is sufficient to demonstrate that the risk is controlled The RMP provides the broader framework and should link the measure to the relevant safety concern, rationale and intended role The RMP is relevant only for routine product information and not for additional measures An RMM can be selected without reference to identified risks, potential risks or missing information in the RMP

Question 10 of 10 What is the primary purpose of user-testing risk-minimisation materials?

To make the materials visually attractive for marketing purposes To demonstrate that the scientific content has been approved by the marketing department To identify whether intended users understand and can correctly use the required information To replace the need for post-implementation effectiveness evaluation

QPPV.com

Knowledge Assessment: GVP Module XVI — Routine and Additional Risk Minimisation Measures

Cookie Settings